185 related articles for article (PubMed ID: 32350415)
1. Genetic and clinical correlates of entosis in pancreatic ductal adenocarcinoma.
Hayashi A; Yavas A; McIntyre CA; Ho YJ; Erakky A; Wong W; Varghese AM; Melchor JP; Overholtzer M; O'Reilly EM; Klimstra DS; Basturk O; Iacobuzio-Donahue CA
Mod Pathol; 2020 Sep; 33(9):1822-1831. PubMed ID: 32350415
[TBL] [Abstract][Full Text] [Related]
2. Cell-in-Cell-Mediated Entosis Reveals a Progressive Mechanism in Pancreatic Cancer.
Song J; Xu R; Zhang H; Xue X; Ruze R; Chen Y; Yin X; Wang C; Zhao Y
Gastroenterology; 2023 Dec; 165(6):1505-1521.e20. PubMed ID: 37657757
[TBL] [Abstract][Full Text] [Related]
3. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
[TBL] [Abstract][Full Text] [Related]
4. A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.
Saha G; Singh R; Mandal A; Das S; Chattopadhyay E; Panja P; Roy P; DeSarkar N; Gulati S; Ghatak S; Ghosh S; Banerjee S; Roy B; Ghosh S; Chaudhuri D; Arora N; Biswas NK; Sikdar N
Mol Med; 2020 Jun; 26(1):59. PubMed ID: 32552660
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
6. Fate of Entosis: From the Beginning to the End in Untreated Advanced Breast Cancer.
Dziuba I; Gawel AM; Tyrna P; Rybczynska J; Bialy LP; Mlynarczuk-Bialy I
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569518
[TBL] [Abstract][Full Text] [Related]
7. Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma.
Deshpande V; Konstantinidis IT; Castillo CF; Hezel AF; Haigis KM; Ting DT; Bardeesy N; Goyal L; Zhu AX; Warshaw AL; Lillemoe KD; Ferrone CR
J Gastrointest Surg; 2016 May; 20(5):953-9. PubMed ID: 26956004
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-506 is up-regulated in the development of pancreatic ductal adenocarcinoma and is associated with attenuated disease progression.
Cheng RF; Wang J; Zhang JY; Sun L; Zhao YR; Qiu ZQ; Sun BC; Sun Y
Chin J Cancer; 2016 Jul; 35(1):64. PubMed ID: 27371108
[TBL] [Abstract][Full Text] [Related]
9. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
10. Entosis: Cell-in-Cell Formation that Kills Through Entotic Cell Death.
Florey O; Kim SE; Overholtzer M
Curr Mol Med; 2015; 15(9):861-6. PubMed ID: 26511711
[TBL] [Abstract][Full Text] [Related]
11. Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas.
Gkountakos A; Mafficini A; Lou E; Malleo G; Salvia R; Calicchia M; Silvestris N; Racila E; Amin K; Veronese N; Brunetti O; Antonini P; Ingravallo G; Mattiolo P; Saponaro C; Nappo F; Simbolo M; Bariani E; Lonardi S; Fassan M; Milella M; Lawlor RT; Scarpa A; Luchini C
Hum Pathol; 2022 Oct; 128():124-133. PubMed ID: 35850360
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-153 is a prognostic marker and inhibits cell migration and invasion by targeting SNAI1 in human pancreatic ductal adenocarcinoma.
Bai Z; Sun J; Wang X; Wang H; Pei H; Zhang Z
Oncol Rep; 2015 Aug; 34(2):595-602. PubMed ID: 26062664
[TBL] [Abstract][Full Text] [Related]
13. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions.
Lin W; Noel P; Borazanci EH; Lee J; Amini A; Han IW; Heo JS; Jameson GS; Fraser C; Steinbach M; Woo Y; Fong Y; Cridebring D; Von Hoff DD; Park JO; Han H
Genome Med; 2020 Sep; 12(1):80. PubMed ID: 32988401
[TBL] [Abstract][Full Text] [Related]
14. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
15. A gene expression signature of epithelial tubulogenesis and a role for ASPM in pancreatic tumor progression.
Wang WY; Hsu CC; Wang TY; Li CR; Hou YC; Chu JM; Lee CT; Liu MS; Su JJ; Jian KY; Huang SS; Jiang SS; Shan YS; Lin PW; Shen YY; Lee MT; Chan TS; Chang CC; Chen CH; Chang IS; Lee YL; Chen LT; Tsai KK
Gastroenterology; 2013 Nov; 145(5):1110-20. PubMed ID: 23896173
[TBL] [Abstract][Full Text] [Related]
16. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
McIntyre CA; Lawrence SA; Richards AL; Chou JF; Wong W; Capanu M; Berger MF; Donoghue MTA; Yu KH; Varghese AM; Kelsen DP; Park W; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Iacobuzio-Donahue CA; Allen PJ; O'Reilly EM
Cancer; 2020 Sep; 126(17):3939-3949. PubMed ID: 32573775
[TBL] [Abstract][Full Text] [Related]
17. Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis.
Dal Molin M; Zhang M; de Wilde RF; Ottenhof NA; Rezaee N; Wolfgang CL; Blackford A; Vogelstein B; Kinzler KW; Papadopoulos N; Hruban RH; Maitra A; Wood LD
Clin Cancer Res; 2015 Apr; 21(8):1944-50. PubMed ID: 25623214
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells.
Simbolo M; Silvestris N; Malleo G; Mafficini A; Maggino L; Cocomazzi A; Veghini L; Mombello A; Pezzini F; Sereni E; Martelli FM; Gkountakos A; Ciaparrone C; Piredda ML; Ingravallo G; Paolino G; Nappo F; Rapposelli IG; Frassinetti L; Saragoni L; Lonardi S; Pea A; Paiella S; Fassan M; Brunetti O; Cingarlini S; Salvia R; Milella M; Corbo V; Lawlor RT; Scarpa A; Luchini C
Mod Pathol; 2023 Sep; 36(9):100251. PubMed ID: 37355152
[TBL] [Abstract][Full Text] [Related]
19. TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma.
Zhou Y; Jin J; Ji Y; Zhang J; Fu N; Chen M; Wang J; Qin K; Jiang Y; Cheng D; Deng X; Shen B
J Transl Med; 2023 Dec; 21(1):872. PubMed ID: 38037073
[TBL] [Abstract][Full Text] [Related]
20. Intratumor Heterogeneity of KRAS Mutation Status in Pancreatic Ductal Adenocarcinoma Is Associated With Smaller Lesions.
Nagawkar SS; Abu-Funni S; Simon E; Bick T; Prinz E; Sabo E; Ben-Izhak O; Hershkovitz D
Pancreas; 2016 Jul; 45(6):876-81. PubMed ID: 26646269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]